gip and glp-1 receptor agonist Frontiers Alimentary Pharmacology & Therapeutics |
Description
However, many anti-obesity agents that have entered human clinical trials have shown unacceptable adverse events
Circulating GLP-1 levels also correlate with severity of critical illnesses (5, 10), sepsis (11), end-stage kidney disease (11), respiratory failure (12), and intestinal ischemia-reperfusion injury (6)
The Lancet , 397 (10286), 1736-1748
Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimers Disease: Study Protocol for a Randomised Controlled Trial (ELAD Study). Trials, vol
By engaging these complementary pathways, mazdutide represents an alternative approach to incretin-based therapy beyond GLP-1 monotherapy
The modified polypeptide can be combined with human albumin to enhance the resistance to DPP-4 and prolong the half-life to 5-6 days
